Endocrine-Sensitive Disease Rate in Postmenopausal Patients with Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationCynthia X. Ma,Vera J. Suman,Souzan Sanati,Kiran Vij,Meenakshi Anurag,A. Marilyn Leitch,Gary W. Unzeitig,Jeremy Hoog,Aranzazu Fernandez-Martinez,Cheng Fan,Richard A. Gibbs,Mark A. Watson,Travis J. Dockter,Olwen Hahn,Joseph M. Guenther,Abigail Caudle,Erika Crouch,Amy Tiersten,Monica Mita,Wajeeha Razaq,Tina J. Hieken,Yang Wang,Mothaffar F. Rimawi,Anna Weiss,Eric P. Winer,Kelly K. Hunt,Charles M. Perou,Matthew J. Ellis,Ann H. Partridge,Lisa A. CareyJAMA ONCOLOGY（2024）引用 0|浏览34暂无评分关键词Neoadjuvant Therapy,Treatment ResponseAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
